Adalta Capital Management’s AbbVie ABBV Stock Holding History

Adalta Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$226K	Hold	897	–	–	0.1%	87
2026 Q1	$195K	Hold	897	–	–	0.09%	87
2025 Q4	$205K	Sell	897 -19	-2%	-$4.33K	0.09%	83
2025 Q3	$212K	Hold	916	–	–	0.1%	78
2025 Q2	$170K	Hold	916	–	–	0.09%	77
2025 Q1	$192K	Buy	+916	New	+$178K	0.1%	72

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Adalta Capital Management's ABBV Position: Q2 2026 in Review

Adalta Capital Management held its AbbVie (ABBV) position steady in Q2 2026 at 897 shares worth $226K. The position accounts for 0.1% of the portfolio, ranked #87.

Adalta Capital Management first reported a position in ABBV in Q1 2025 and has held it in 6 quarters since. 4,221 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Adalta Capital Management held 897 shares of AbbVie worth $226K as of Q2 2026.
Adalta Capital Management left its AbbVie share count unchanged in Q2 2026.
AbbVie made up 0.1% of Adalta Capital Management's portfolio in Q2 2026, its #87 holding.
Adalta Capital Management first reported a position in AbbVie in Q1 2025 and has held it in 6 quarters since.
4,221 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Adalta Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.